



# Biotech Daily

Thursday July 31, 2025

*Daily news on ASX-listed biotechnology companies*

- \* ASX, BIOTECH DOWN: STARPHARMA UP 5%; MEDICAL DEVELOPMENTS DOWN 11%
- \* RMIT DEVELOPS WEARABLE WOUND MONITORING SENSORS
- \* DR BOREHAM'S CRUCIBLE: TELIX PHARMACEUTICALS
- \* MEDADVISOR RECEIPTS DOWN 25% TO \$88m
- \* MEDICAL DEVELOPMENTS UNAUDITED REVENUE UP 18% TO \$39m
- \* NEXT SCIENCE H1 RECEIPTS DOWN 19% TO \$14m
- \* IMEX H1 RECEIPTS DOWN 7% TO \$11m
- \* IMPEDIMED RECEIPTS UP 22% TO \$14m
- \* RESONANCE RECEIPTS UP 72% TO \$14m
- \* CANN RECEIPTS DOWN 21% TO \$13m
- \* HYDRIX RECEIPTS DOWN 18% TO \$10m
- \* CONTROL BIONICS RECORD RECEIPTS UP 8% TO \$6m; 0.7 QUARTERS CASH
- \* STARPHARMA RECEIPTS DOWN 42% TO \$5m
- \* PAINCHEK RECEIPTS UP 32% TO \$3.5m
- \* MICRO-X RECEIPTS DOWN 60% TO \$3m
- \* PRESCIENT PLACEMENT RAISES \$3m; TOTAL \$9.8m
- \* ISLAND COMPLETES UP-TO \$4m GALIDESIVIR PURCHASE
- \* ACRUX, SERVACURE TO SELL DAPSONE FOR ACNE IN SAUDI ARABIA
- \* NEUROSCIENTIFIC, QIMR TO PRODUCE STEMSMART
- \* IMAGION REQUESTS 'CAPITAL RAISING' TRADING HALT
- \* NYRADA REQUESTS 'CAPITAL RAISING' TRADING HALT
- \* HERAMED REQUESTS 'CAPITAL RAISING' TRADING HALT
- \* PLATINUM INCREASES, DILUTED TO 9% OF AMPLIA
- \* ALLAN MOSS, BLUEFLAG INCREASE, DILUTED BELOW 5% OF AMPLIA
- \* PROF KHALIL SHAHIN, AFO INVESTMENTS TAKE 17% OF VITURA
- \* ELIZABETH JANSEN, STANFORD REDUCE TO 13% OF VITURA
- \* MARK AZZI TAKES 17% OF NYRADA

## MARKET REPORT

The Australian stock market fell 0.16 percent on Thursday July 31, 2025, with the ASX200 down 13.6 points to 8,742.8 points. Ten of the Biotech Daily Top 40 companies were up, 25 fell and five traded unchanged.

Starpharma was best, up 0.5 cents or 5.3 percent to 10 cents, with 684,370 shares traded. Cyclopharm, Neuren and Prescient climbed four percent or more; Compumedics and Nova Eye rose more than three percent; Clinuvel, Immutep and Telix were up more than one percent; with Clarity, Cochlear, Pro Medicus and Resmed up less than one percent.

Medical Developments led the falls, down 7.5 cents or 10.95 percent to 61 cents, with 714,021 shares traded. Impedimed lost 9.6 percent; Cynata was down 8.8 percent; Paradigm shed 7.8 percent; Medadvisor and Resonance were down five percent or more; Actinogen, Avita, Syntara and Universal Biosensors fell four percent or more; Botanix, Imugene and Micro-X were down more than three percent; 4D Medical, Alcidion, Aroa, EBR, Emvision, Mesoblast, Polynovo and Proteomics shed more than two percent; Dimerix and Orthocell were down more than one percent; with CSL, Genetic Signatures and SDI down by less than one percent.

## ROYAL MELBOURNE INSTITUTE OF TECHNOLOGY

RMIT says it has developed a wearable wound monitoring device using silicon sensors that may “reduce infection risks by minimizing the need for frequent physical contact”. RMIT said the proof-of-concept device was “designed for reuse, making it more cost-effective and practical than disposable smart bandages and other emerging wound monitoring technologies”.

The Institute said standard methods required “regular removal of wound dressings for assessments, often delaying crucial interventions, whereas this invention monitors healing remotely via a Bluetooth connection”.

RMIT said the device was based on an RMIT-patented technology and had flexible inflammation, pH (potential of hydrogen) and temperature sensors that could be placed on or next to a wound under dressings to continuously track healing indicators.

The Institute said high temperatures signaled inflammation or infection, and changes in pH levels indicated different stages of wound healing.

RMIT said it conducted a study of the device by “simulating conditions it would encounter in wound management” and had placed the device on a human arm to demonstrate that it confirmed well to the curved surface.

The Institute said the study, titled ‘Multiplexed cutaneous wound monitor for point-of-care applications’ was published in Advanced Nanobiomed Research, with the full article available at: <https://advanced.onlinelibrary.wiley.com/doi/10.1002/anbr.202500142>.

RMIT lead inventor Dr Peter Elango said the study was designed “to show that this type of alternative monitoring technology is possible, and we are now ready to work with industry partners to develop it for clinical trials”.

“Its components are biocompatible and fit seamlessly into existing manufacturing workflows and processes, potentially bringing the cost below \$5.00 per unit when produced at scale,” Dr Elango said.

RMIT said the researchers developing the device had previously developed bedding sensors for use in aged care to monitor sleep quality and comfort and a wearable heart monitor progressing towards commercialization with Perth’s Lubdub Technologies.

## DR BOREHAM'S CRUCIBLE: TELIX PHARMACEUTICALS

**By TIM BOREHAM**

**ASX Code:** TLX

**Share price:** \$21.05; **Shares on issue:** 338,399,059; **Market cap:** \$7.1 billion

**Co-founder and chief executive officer:** Dr Christian Behrenbruch

**Board:** Tiffany Olson (chair), Dr Behrenbruch, Dr Mark Nelson, Jann Skinner, Marie McDonald (chairman Kevin McCann retired in May 2025)

**Financials (June quarter 2025):** revenue \$US204 million (up 63%)

**Calendar 2024 year:** revenue \$783.2 million (up 55.85%), net profit after tax \$49.9 million (up 9.6-fold)

**Major shareholders:** Gnosis Verwaltungsgesellschaft (Dr Kluge) 6.1% Elk River Holdings (Dr Behrenbruch) 6.3%, Grand Pharma (China Grand Pharmaceuticals) 1.8%.

With multiple clinical trials and approval applications in train, nuclear medicine superstar Telix is like one of those irritatingly brilliant, all-round students.

We're thinking of the straight A school captain who stars in the school play, while padding up for the First XI in between clarinet lessons.

But when Goody Two Shoes' Latin grade slips to B+, panic ensues - mainly on the part of overbearing 'parents' (investors).

Last week, Telix experienced the corporate version of such angst when it revealed the US Securities and Exchange Commission (SEC) had subpoenaed "various documents and information".

While disclosing the information in a report titled 'Telix Reports \$204m Revenue, Up 63% YOY' the company said the SEC subpoena "does not extend to Telix commercial and late-stage precision medicine products including Illuccix, Gozellix, Zircaix, Pixclara and Scintimun".

The company dubbed the entreaty a "fact finding request", but investors birched the stock by 15 percent.

Telix has a nearer-term focus on winning US Food and Drug Administration approval for two imaging products and says the longer-term therapy programs will continue unchanged.

But the mysterious episode is not the first time that Telix has slipped up.

In April, the FDA knocked back Telix's marketing application for its brain cancer (glioma) diagnostic, telling the company to do more homework.

Management said the setback (by way of a Complete Response Letter) was merely temporary and the company would do what Headmaster requested.

A year ago, the FDA also rejected the company's filing for its kidney cancer diagnostic Zircaix, on account of an "unacceptable manufacturing defect".

Telix founder, CEO and head prefect Dr Chris Behrenbruch dubbed the glitches were "relatively minor and fixable".

Indeed, the company re-filed the application and the market awaits an FDA decision by the end of August.

### **Telix machine is clicking along**

To date, Telix has derived most of its revenue in the US, from its approved prostate cancer imaging agent Illuccix.

Illuccix is a kit for preparing gallium-68 gozetotide - more commonly known as a PSMA-11 injection - for positron emission tomography (PET) scans.

Illuccix is used for prostate cancer patients suspected of having either metastasized growths, or a recurrence based on elevated PSA (prostate-specific antigen) levels.

Elevated levels in the blood of PSA, a protein, can be a marker of prostate cancer.

PSMA (prostate-specific membrane antigen) is a protein found on the surface of prostate cancer cells.

Illucix is approved in 17 countries, including the US, the UK, Brazil, Germany, France, Canada and Australia.

In March, the FDA approved a second diagnostic, Gozellix (for metastatic castrate resistant prostate cancer).

Telix hopes to launch Gozellix in the US in the current quarter by October.

### **A bit of history**

Dr Behrenbruch founded Telix in 2015 out of a "deep frustration" that there was a burgeoning interest in nuclear medicine technologies, but few commercial players.

In early 2017, Telix acquired the Dresden-based radio-pharmaceutical outfit Therapiea, founded by Dr Andreas Kluge.

Dr Kluge retired from the board in September last year.

Telix listed in November 2017, after raising \$50 million at 65 cents apiece.

In November 2024, the company listed on the Nasdaq, having abandoned a \$300 million initial public offer in favour of a \$650 million non-US corporate bond issue.

Dr Behrenbruch was the executive director of the now defunct Factor Therapeutics and was also on the board of the very un-defunct pancreatic cancer tearaway, Amplia Therapeutics.

In 2020, Telix inked a 10-year deal with China Grand Pharmaceutical, worth “up to” \$US225 million, The Hong Kong-based entity became the exclusive partner in greater China for any approved Telix therapy.

Telix remains Melbourne based, but most of its commercial activity is in the US.

### **Good golly, it's Gozellix**

In March this year, the FDA approved the company's gallium isotope-based Gozellix, for PET scanning of lesions showing PSMA.

While not an expansion to a completely new indication, Gozellix extends the company's US prostate cancer imaging market reach by an estimated five to 10 percent.

Gozellix is for prostate cancer patients with suspected metastasis, who are candidates for initial definitive therapy (prostate removal or broader radiation treatment).

It's also for those with suspected recurrence, based on elevated PSA levels.

“The ability to reliably deliver the product much further from its point of production means Gozellix can reach PET cameras that are currently not served by any PSMA imaging providers,” the company says.

Gozellix has a longer shelf life of up to six hours, about three times more than Illucix. It can also be used on older scanning machines.

### **On the acquisition trail**

To expand its repertoire and bolster its manufacturing oomph, Telix has continued an acquisitive splurge.

In January, Telix acquired a “proprietary novel biologics technology” from antibody engineering company Imaginab Inc.

The platform has small, engineered antibody formats that enable specific radiation targeting of cancer.

The deal delivers a “state-of-the-art” research facility in Los Angeles, adding to existing capacity at Sacramento, Angleton (Texas) and across the border in Vancouver.

In September 2024, Telix spent \$388 million to acquire RLS Radiopharmacies, to expand its North American manufacturing and distribution footprint.

RLS derives revenue from providing radio-pharmacy products to third party clients.

In April, the company bought the Austin-based Isotherapeutics (radio-chemistry services) and the Canadian radio-isotope producer Artms Inc.

## **Let's get clinical**

It's hard to do justice to Telix's extensive clinical program in a few paragraphs, but here goes ...

By the end of the year, the company should unveil an initial safety and dosing readout for its phase III prostate cancer therapy candidate, the lutetium-based TLX-591.

The study, Prostact Global, has enrolled 30 men for the part one phase. These patients have PSMA-positive metastatic castrate-resistant prostate cancer, with the standard-of-care chemotherapy drugs, or the standard-of-care alone.

To date, TLX-591 has been evaluated in 242 patients across eight phase I/II studies, with "evidence of anti-tumor effect and a clear dose response profile for key measures of efficacy".

Telix also has mid-stage brain and kidney cancer therapy programs and another one for bone marrow conditioning; as well as earlier stage programs for musculo-skeletal conditions including soft tissue sarcoma, bone metastases and "pain palliation".

Readers should peruse the company 127-page investor presentation from June 11, but only if they are feeling strong.

<https://announcements.asx.com.au/asxpdf/20250611/pdf/06kn42znh0567z.pdf>.

## **Finances and performance**

Telix reported revenue of \$US204 million for the June 2025 quarter, up 63 percent year-on-year and a 10 percent increment on the March 2025 quarter.

(As of January this year, the company reports in US dollars.)

Sales of Illuccix accounted for \$US154 million, up 25 percent year-on-year. RLS contributed \$US46 million of sales, 39 percent higher than the March quarter.

Dr Behrenbruch notes Illuccix dose volumes rose seven percent, quarter-on-quarter.

He says despite "emerging competitive pricing pressure" Telix has "effective strategies" to maintain average selling prices.

Not irrelevantly, in July, Gozellix was granted a permanent Healthcare Common Procedure Coding System code.

Telix expects to obtain transitional pass-through (TPT) status, which provides additional Medicare reimbursement to hospitals using innovative medical devices or drugs. TPT should apply from October 1 with reimbursement of around \$US1,000 per dose, almost twice that applying to Illuccix.

In calendar 2024, Telix expended \$US195 million on research and development, up 50 percent. This year the number should be 20 to 25 percent higher again.

Telix has maintained calendar 2025 guidance of \$US770 million to \$US800 million, having chalked up first half-year revenue of \$US390 million. We'll know about the innards of Telix's financials at its full-year results on August 21.

Over the last 12 months Telix shares have irradiated between \$17.44 (early September last year) and a record \$31.14 in late January this year. In November 2017 the shares were worth 13 cents.

### **Telix trumps tariffs with US manufacturing**

Telix says it won't be affected by Trump's drug pricing and tariff proposals.

Given Telix's just-in-time products are made in the US out of necessity, they are as American as apple pie and a Colt AR-15 rifle under the bed.

"This will continue to be the case for new products the company expects to launch in 2025" the company says.

As for drug pricing, the Trump administration plans to benchmark certain local therapeutics against those charged in the cheapest of the industrialized nations.

Telix reckons it's in the clear because "localized production makes international pricing comparisons challenging to benchmark". In any event, the company promises "pharmaco-economically defensible" pricing.

### **What the brokers say**

Broking analysts maintain their faith in Telix, despite the distraction of the SEC probe (if we can call it that) and stiffening prostate imaging competition.

Broker Jefferies says such SEC entreaties are common, but the issues might take two years or so to resolve.

UBS suggests any disclosure shortcomings may relate to Telix's dual ASX/Nasdaq listing, with the company needing to satisfy different requirements across the Pacific. On competition, UBS notes that the seven percent uptick in Illucix sales shows Telix is winning market share in a hotter market.

The firm believes the launch of Gozellix (and its TPT status) has relieved some of the pricing pressure.

UBS values Telix at \$36 a share, while Jefferies and Bell Potter plump for a \$34 price target. The latter does so on the expectation of FDA approval of Zircaix.

UBS says the current valuation assumes “total scientific and clinical failure” of the therapeutic programs.

Valuing the stock at \$35, Wilsons says Gozellix provides “exciting upside” and Telix has “so many options available to it both competitively and operationally”.

The only Grumpy Bob is Morningstar, which in April described Telix as overvalued by about 40 percent.

The research house opined Telix’s product pipeline remained “commercially unproven in an increasingly competitive market.”

### **Dr Boreham’s diagnosis:**

Telix faces a pile of homework, but we concur the company can remain dux of the radio-imaging class despite the regulatory issues.

We should stress that Telix is solidly profitable: UBS plugs in a net profit of \$138 million for the current year, rising to \$292 million in 2026 and \$480 million in 2027.

Telix cites a current US prostate cancer imaging market at US\$2.5 billion to \$US3.5 billion.

But with expanded indications, this figure swells to \$US6.7 billion across 1.7 million scans annually.

One might think the medical world had nuclear diagnostics down pat by now, but evidently there are isotopes and there are isotopes.

In the past, Dr Behrenbruch has described Zircaix as potentially bigger for Telix than Illuccix.

Not that he expects the prostate business to slow down.

Beyond imaging, if Telix can crack a better therapy for the key cancers in its remit, then its \$7 billion market valuation looks only the start.

***Disclosure: Dr Boreham is not a qualified medical practitioner and does not possess a doctorate of any sort. So, it goes. But give him an isotope and he will take a stab at where to stick it, so it glows***



## MEDADVISOR

Medadvisor says receipts from customers for the year to June 30, 2025 fell 25.1 percent to \$88,391,000, compared to the previous corresponding period.

Medadvisor said that customer receipts from contracts for its patient medication management platform with pharmacies in the three months to June 30, 2025 were down 14.2 percent to \$19,497,000, compared to the prior corresponding period.

Medadvisor managing-director Rick Ratliff said “challenges across the US healthcare ecosystem, including restructuring at ... [pharmacies] and ongoing budget constraints within pharmaceutical sponsors, led to delays in the launch of several health programs”.

“While vaccine revenue increased compared to the prior corresponding period, some vaccine campaigns also experienced launch delays due to shifting government guidance and pharmacy network readiness,” Mr Ratliff said. “As a result, a number of contracted programs, featuring several in new brand categories, were deferred into the first half of 2025-’26, impacting both revenue and margins in the fourth quarter.”.

“Post quarter, the sale of the business to Jonas Software completed for a headline price of \$35 million,” Mr Ratliff said. “The majority of the initial proceeds were used to repay debt obligations, leaving the company debt-free” (BD: Jul 7, 2025).

Medadvisor said it had a cash burn of \$2,014,000 for the three months, with cash and equivalents of \$12,552,000 at June 30, 2025 compared to \$15,578,000 at June 30, 2024. Medadvisor fell 0.4 cents or 5.1 percent to 7.5 cents with 1.9 million shares traded.

## MEDICAL DEVELOPMENTS INTERNATIONAL

Medical Developments says unaudited revenue for the year to June 30, 2025 was up 17.8 percent to \$39.1 million, compared the previous corresponding period.

Medical Developments said customer receipts for the year to June 30, 2025 were up 10.3 percent to \$38,346,000, with three-month receipts up 2.2 percent to \$8,508,000.

The company said revenue from its pain management product Pentrox was \$26.2 million for the year driven by higher pricing and increased demand from Europe, with respiratory revenue of \$12.8 million due to “stronger demand in Australia and ... growth in the US”.

Medical Developments said it had a cash burn of \$981,000 for the three months, with cash and equivalents of \$17,837,000 at June 30, 2025 compared to \$9,735,000 the prior year.

Medical Developments fell 7.5 cents or 10.95 percent to 61 cents.

## NEXT SCIENCE

Next Science says customers receipts for the six months to June 30, 2025 fell 18.6 percent to \$US9,309,000 (\$A14,432,000) compared to the prior corresponding period.

Next Science said that receipts from customers from sales of its Xperience and Blastx for infections in wound care fell 23.2 percent for the three months to June 30, 2025 to \$US4,627,000, compared to the previous corresponding period.

The company said product sales fell “as higher partner sales and direct sales of Blastx and Xperience were offset by a decline in the [durable medical equipment] channel”.

Next Science said it had cash burn of \$US1,540,000 for the three months, with cash and equivalents of \$US971,000 at June 30, 2025, leaving it with 0.9 quarters cash.

The company said it had a binding asset purchase agreement and did not expect the current level of operating cash flows to continue at the current level.

Earlier this month, Next Science said it would sell “substantially all” of its assets and subsidiaries for \$US50 million to Milan’s Demetra Holdings SpA (BD: Jul 1, 2025).

Next Science fell 0.25 cents or 1.75 percent to 14 cents.

### IMEX HEALTH SERVICES

Imex says receipts from customers for the six months to June 30, 2025, were down 7.2 percent to \$11,062,000, compared to the previous corresponding period.

Imex said receipts for the three months to June 30, 2025 from its Aquila Enterprise radiology services and software licencing fell 21.1 percent to \$5,616,000, compared to the prior corresponding period.

Imex managing-director Dr German Arango said the President of Colombia had attempted to reform the healthcare system “aimed at eliminating the private insurance company sector” and although the reforms were rejected by the Colombian Congress they had slowed “funding to both the public and private medical insurance sectors”.

Imex said it provided its software and services in 18 countries including Colombia.

Imex said it was \$143,000 cash flow positive for the three months, with cash and equivalents of \$2,495,000 at June 30, 2025, compared to \$1,892,000 at June 30, 2024.

Imex fell three cents or 9.1 percent to 30 cents.

### IMPEDIMED

Impedimed says receipts from customers for the year to June 30, 2025 were up 21.6 percent to \$13,980,000, compared to the previous corresponding period.

Impedimed said customer receipts from the three months to June 30, 2025 were up 27.4 percent to \$3,784,000, due primarily to “a significant lift” in US sales of its Sozo bio-impedance spectroscopy system for lymphoedema, heart failure and malnutrition.

The company said it had “record Sozo core business total contract value as a direct result of the work undertaken to build a high-quality pipeline and strengthen the sales team”.

Impedimed said it had a cash burn of \$3,530,000 for the three months, with cash and cash equivalents of \$22,248,000 at June 30, 2025 compared to \$24,632,000 at June 30, 2024.

Impedimed fell half a cent or 9.6 percent to 4.7 cents with 4.9 million shares traded.

### RESONANCE HEALTH

Resonance says receipts from customers for the year to June 30, 2025 were up 72.2 percent to \$13,965,000, compared to the previous corresponding period.

Resonance said receipts from sales of its magnetic resonance imaging-based liver and heart diagnostics as well as its clinical research services fell 27.9 percent for the three months to June 30, 2025 to \$3,774,000, compared to the prior corresponding period.

The company said it was \$169,000 cash flow positive for the three months, with cash and equivalents of \$2,977,000 at June 30, 2025, compared to \$6,854,000 at June 30, 2024.

Resonance fell 0.2 cents or five percent to 3.8 cents.

### CANN GROUP

Cann says receipts from customers for the year to June 30, 2025 fell 20.9 percent to \$13,054,000, compared to the previous corresponding period.

Cann said customer receipts from sales of its marijuana products fell 14.3 percent to \$2,855,000 for the three months to June 30, 2025, compared to the prior period.

The company said it had a cash burn of \$2,364,000 for the three months, with cash and cash equivalents of \$10,000 at June 30, 2025, leaving it with no available funding.

Cann said it expected a Research and Development Tax Incentive, was in discussions with lenders to restructure debt and continued to reduce net cash outflows.

Cann was up 0.2 cents or 14.3 percent to 1.6 cents with two million shares traded.

### HYDRIX

Hydrix says receipts from customers for the year to June 30, 2025 fell 17.7 percent to \$10,082,000, compared to the previous corresponding period.

Hydrix said customer receipts from its product services and sales of its cardiovascular devices for the three months to June 30, 2025 were down 37.8 percent to \$1,919,000. The company said it had a cash burn of \$892,000 for the three months, with cash and cash equivalents of \$298,000 at June 30, 2025, compared to \$914,000 at June 30, 2024, leaving it with 0.61 quarters of available funding; and it did not expect its current level of net operating cash flows to continue with “a director and major shareholder [providing] a \$2.0 million ‘letter of comfort’ to the business through September 30, 2025”. Hydrix fell 0.1 cents or 5.6 percent to 1.7 cents.

### CONTROL BIONICS

Control Bionics says receipts from customers for the year to June 30, 2025 were up 8.0 percent to a record \$5,736,000, compared to the previous corresponding period.

Control Bionics said customer receipts from sales of its Neuronode electromyography-based, thought-to-computer technology for the three months to June 30, 2025 were up 39.9 percent to \$1,354,000, compared to the prior corresponding period.

The company said it had a cash burn of \$820,000 for the three months, with cash and cash equivalents of \$595,000 at June 30, 2025, leaving it with 0.7 quarters of cash.

Control Bionics said it expected “continued improvement in net operating cash flows”, increased receipts in Australia and the US and had taken a loan against its expected Federal Research and Development Tax Incentive.

Control Bionics was up 0.3 cents or 8.1 percent to four cents.

### STARPHARMA HOLDINGS

Starpharma says receipts from customers for the year to June 30, 2025 fell 41.5 percent to \$4,924,000, compared to the previous corresponding period.

Last year, Starpharma said it had customer receipts the year to June 30, 2024 of \$8,412,000, which included a one-off payment of \$6.54 million from Mundipharma for terminating its Vivagel BV licence and supply agreement (BD: Aug 14, 2023).

Today, the company said receipts for the three months to June 30, from sales of Viraleze nasal spray for respiratory viruses and Vivagel for bacterial vaginosis were up 97.0 percent to \$2,049,000; it had a cash burn of \$2,028,000 for the three months, with cash and equivalents of \$15,407,000 at June 30, 2025 compared to \$23,360,000 the prior year. Starpharma was up half a cent or 5.3 percent to 10 cents.

### PAINCHEK

Painchek says receipts from customers for the year to June 30, 2025 were up 32.0 percent to \$3,489,000, compared to the previous corresponding period.

Painchek said sales receipts from its pain monitoring applications and software licences for the three months to June 30, 2025 were up 41.0 percent to \$1,015,000.

Painchek chief executive officer Philip Daffas said US sales were expected to begin following clearance which “may significantly enhance Painchek’s [revenue]”.

The company said was \$19,000 cash flow positive for the three months, with cash and cash equivalents of \$1,617,000 compared to \$3,562,000 at June 30, 2024.

Painchek fell 0.3 cents or 7.9 percent to 3.5 cents with 4.2 million shares traded.

### MICRO-X

Micro-X says receipts from customers for the year to June 30, 2025 were down 60.1 percent to \$2,788,000, compared to the prior corresponding period.

Last year, Micro-X said it had record customer receipts for the year to June 30, 2024, up 79.5 percent to \$6,989,000, compared to the prior year (BD: Jul 29, 2024).

Today, the company said sales of its Rover mobile digital x-ray machines and Argus bomb detection systems for the three months to June 30, 2025 fell 41.2 percent to \$752,000.

Micro-X said it had a cash burn of \$3,494,000 for the three months, with cash and cash equivalents of \$3,242,000 at June 30, 2025, leaving it with 0.92 quarters of funding.

The company said it had \$1.9 million in overdue receivables, had a Radium Capital RDTI loan and was "targeting increased sales of its Rover Plus product".

Micro-X fell 0.3 cents or 3.5 percent to 8.3 cents with 1.6 million shares traded.

### PRESCIENT THERAPEUTICS

Prescient says it has raised \$2,978,500 in a placement at four cents a share, following its \$6,900,000 share purchase plan, after final reconciliation.

On Tuesday, Prescient said that it had raised \$6.8 million at four cents a share, a 16.7 percent discount to the 15-day volume weighted average price, in a share purchase plan and requested a trading halt for a follow-on placement (BD: Jul 29, 2025).

Today, the company said the total raised was about \$9.8 million, with the funds to be used for the continued phase IIa clinical development of PTX-100 for blood cancer.

Prescient was up 0.2 cents or 4.4 percent to 4.7 cents with 1.1 million shares traded.

### ISLAND PHARMACEUTICALS

Island says it has completed its up-to \$US2.5 million (\$A3.8 million) acquisition of the Durham, North Carolina-based Biocryst Pharmaceuticals' galidesivir anti-viral program.

Last year, Island said it had paid Biocryst \$US50,000 for a 12-month option to acquire the galidesivir molecule which had exhibited anti-viral activity against Ebola, Zika, yellow fever and Marburg and earlier this month said it had exercised its right to acquire the galidesivir anti-viral from Biocryst for up-to \$US2.5 million (BD: Sep 11, 2024; Jul 9, 2025).

Today, Island said it intended to submit documentation on the galidesivir program to the US Food and Drug Administration by October and meet the regulator by 2026 and potentially begin an animal study of galidesivir for Marburg virus "shortly thereafter".

Island was unchanged at 17 cents.

### ACRUX

Acrux says Muharraq, Bahrain's Servacure Trading WLL will market, sell and distribute its dapsona five percent topical gel for acne vulgaris in Saudi Arabia.

Acrux said the contract with Servacure was for 10 years with options for renewal.

The company said Servacure would "assume responsibility for obtaining regulatory approval as well as coordinating manufacturing for the territory and will pay ... a fixed fee per unit for the aggregate unit volume of all product shipped to customers".

Acrux managing-director John Warmbrunn said Servacure had "a demonstrated track record of commercializing their products in the Saudi marketplace and we look forward to a long-term relationship with them across the range of products in our portfolio".

Acrux fell 0.2 cents or 11.1 percent to 1.6 cents with 2.7 million shares traded.

### NEUROSCIENTIFIC BIOPHARMACEUTICALS

Neuroscientific says it has begun transferring the Stemsmart manufacturing process from Royal Perth Hospital to Brisbane's QIMR Berghofer.

Last month, Neuroscientific said it completed its acquisition of Perth's Isopogen WA and its Stemsmart technology for scrip (BD: Jun 27, 2025).

Today, the company said Isopogen had signed a manufacturing contract with the Queensland Institute of Medical Research Berghofer's (QIMR) Q-Gen Cell Therapeutic for the manufacture of its Stemsmart mesenchymal stromal cells.

Neuroscientific said Q-Gen was "one of the largest cell therapy contract manufacturers in Australia, with 13 cleanrooms dedicated to cell manufacturing and quality control".

Neuroscientific chief executive officer Nathan Smith said the company was "very pleased to be partnering with Q-Gen given their extensive experience in manufacturing, process development and ... production of biologic products for clinical trials".

"This relationship will allow the company to scale the manufacturing of its Stemsmart technology to address substantial market opportunities," Mr Smith said.

Neuroscientific fell half a cent or 2.1 percent to 23.5 cents.

### IMAGION BIOSYSTEMS

Imagion has requested a trading halt pending "the release of information by the company to the market relating to a capital raising through lead manager CPS Capital".

Trading will resume on August 4, 2025, or on an earlier announcement.

Imagion last traded at 1.5 cents.

### NYRADA INC

Nyrada has requested a trading halt "pending an announcement by the company to the market regarding a proposed capital raising".

In its Appendix 4C, Nyrada said it had a cash burn of \$1,852,000 for the three months to June 30, 2025, with cash and cash equivalents of \$2,931,000, leaving it with 1.6 quarters of available funding.

Trading will resume on August 4, 2025, or on an earlier announcement.

Nyrada last traded at 37 cents.

### HERAMED BIOSYSTEMS

Heramed has requested a trading halt pending "an announcement ... regarding a proposed capital raise".

Trading will resume on August 4, 2025, or on an earlier announcement.

Heramed last traded at 1.2 cents.

### AMPLIA THERAPEUTICS

Platinum Asset Management Ltd says it has increased its substantial holding in Amplia and has been diluted from 40,318,194 shares (10.39%) to 45,313,932 shares (9.31%).

Sydney's Platinum said it sold shares between May 16 and July 16, 2025 and bought 8,695,653 shares in a placement on July 29, 2025 for \$2,000,000, or 23 cents a share.

Last week, Amplia said it had raised \$25 million at 23 cents a share in a placement, with a fully-underwritten, \$2.5 million share purchase plan to follow (BD: Jul 23, 2025).

Amplia was unchanged at 24 cents with 6.4 million shares traded.

### AMPLIA THERAPEUTICS

Sydney's Allan Moss and Blueflag say they increased and have been diluted below the substantial shareholder level in Amplia.

Mr Moss and Blueflag said they bought 434,783 shares for \$100,000 or 23 cents a share on July 29, 2025 and were diluted below the substantial level (see above).

### VITURA HEALTH

AFO Investments Pty Ltd director Prof Khalil Shahin says he has increased his holding in Vitura from 87,662,474 shares (13.24%) to 114,464,236 shares (17.29%).

The Adelaide-based AFO and Prof Shahin said they acquired 26,801,762 shares, of which 25,000,000 were bought off-market on July 29, 2025 at 5.72 cents a share.

Separately, Vitura said Prof Shahin had "become the largest shareholder in the company". Earlier this year, the company said it had raised \$5,171,196 in a placement at 6.912 cents a share to AFO Investments to fund a \$5.9 million acquisition of Brisbane marijuana company Livelihood Health Pty Ltd (BD: Feb 12, 2025).

Vitura was unchanged at 6.9 cents.

### VITURA HEALTH

Elizabeth Jansen says as trustee for Stanford Investment Trust she has reduced her holding in Vitura from 113,365,596 shares (17.27%) to 85,621,544 shares (12.93%).

The Gold Coast-based Ms Jansen said she sold 25,000,000 shares off-market on July 29, 2025 for \$1,430,000, or 5.72 cents a share, and sold a further 2,744,052 shares between February 17 and June 13, 2025 at a range of prices.

### NYRADA

Nyrada says Mark Azzi has increased his substantial shareholding from 32,583,494 2,427,243 Chess depository interests (CDIs) (15.45%) to 34,947,597 CDIs (16.57%).